GlassScriptPhysician profile
Kori E Anderson
NPI 1902227630
$8,022.59
in general payments reported to CMS, 2019-2025
29 companies · $714 in 2025
The $714 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,484 · 2022: $1,534 · 2023: $1,708 · 2024: $2,581 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,003.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,155.83 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,125.78 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $929.73 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $672.17 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $591.44 | 2021-2025 | Qelbree, Xyosted, Qelbree |
| Alkermes, INC. | $455.24 | 2021-2025 | Lybalvi, Aristada |
| Tris Pharma INC | $343.28 | 2023-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $297.67 | 2022-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $295.93 | 2021-2022 | |
| Axsome Therapeutics, INC. | $272.23 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $217.91 | 2021-2022 | |
| Antares Pharma, INC. | $205.10 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Neurocrine Biosciences, INC. | $191.05 | 2021-2025 | Ingrezza |
| Corium, LLC | $186.01 | 2022-2024 | Azstarys |
| Lundbeck LLC | $172.93 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $149.58 | 2023 | Wakix |
| Intra-Sana Laboratories | $130.47 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Novo Nordisk INC | $112.55 | 2021-2023 | Wegovy |
| Lilly USA, LLC | $88.23 | 2023-2025 | Zepbound |
| Bausch Health US, LLC | $85.29 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $78.36 | 2024 | Quviviq |
| Pfizer INC. | $75.94 | 2023-2024 | |
| Halozyme INC | $47.97 | 2023 | |
| Ironshore Pharmaceuticals INC. | $45.93 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $34.61 | 2024 | Fanapt |
| Biohaven Pharmaceuticals, INC. | $17.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.95 | 2022 | |
| Adlon Therapeutics L.P. | $14.95 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kori Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.